Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway

Elisa Alghisi, Michele Malagola, Cristina Santoriello, Martin Distel, Christiaan Henkel, Cristina Skert, MD, Carla Filì, MD, Cesare Bergonzi, Simone Perucca, Alessandro Turra, Andrea Di Palma, Valeria Cancelli, Rossella Ribolla, Federica Cattina, Simona Zedda, Simona Bernardi, Domenico Russo, Marina Mione

Blood (2012) 120 (21): 4676.

https://doi.org/10.1182/blood.V120.21.4676.4676

Published: 2012

Journal Articles

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Matilde Y Follo, PhD, Carlo Finelli, MD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Carla Filì, MD, Costanza Bosi, MD, Marilisa Quaranta, PhD, Stefania Paolini, MD, Anna Maria Billi, PhD, Marco Gobbi, MD, Michele Baccarani, MD, Domenico Russo, Giovanni Martinelli, MD, Lucia Manzoli, MD, Lucio Cocco, MD

Blood (2012) 120 (21): 1289.

https://doi.org/10.1182/blood.V120.21.1289.1289

Published: 2012

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Blood (2010) 116 (21): 4029.

https://doi.org/10.1182/blood.V116.21.4029.4029

Published: 2010

Journal Articles

Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and SCH66336) on Acute Leukemia Human Tumor Cell Lines.

Domenico Russo, MD, Angela Michelutti, MD, Michele Malagola, MD, Tiziana Grafone, MD, Emanuela Ottaviani, MD, Anna Candoni, MD, Cristina Skert, MD, Carla Filì, MD, Maurizio Castelli, MD, Giovanni Martinelli, MD, Daniela Damiani, MD, Michele Baccarani, MD

Blood (2005) 106 (11): 4416.

https://doi.org/10.1182/blood.V106.11.4416.4416

Published: 2005

NARROW

Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and SCH66336) on Acute Leukemia Human Tumor Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study

Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and SCH66336) on Acute Leukemia Human Tumor Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only